БИОЛОГИЧЕСКАЯ АКТИВНОСТЬ ДИХЛОРАЦЕТАТА НАТРИЯ: КОНЦЕПЦИИ И МЕХАНИЗМЫ (ОБЗОР ЛИТЕРАТУРЫ)

Биологическая активность дихлорацетата натрия изучается в медицине на протяжении последних сорока пяти лет, между тем, представленный обзор является первым в отечественной литературе и призван привлечь внимание исследователей к данной проблематике. В экспериментально-клинических исследованиях демонстрируется эффективность дихлорацетата натрия как цитопротектора при ряде патологических процессов, сопровождающихся митохондриальной дисфункцией, а также противоопухолевая активность. Механизм его действия связан с активацией пируватдегидрогеназного комплекса и, как следствие, энергетического метаболизма. В нормальных клетках, находящихся в условиях гипоксии, это приводит к оптимизации расходования кислорода, предотвращению закисления среды. В атипичных клетках при этом происходит инверсия метаболизма с интенсификацией свободнорадикальных процессов, активацией каспазного ферментного каскада, снижением активности пропролиферативных и проангиогенетических транскрипционных факторов.

дихлорацетат натрия, митохондриальная дисфункция, пируватдегидрогеназа, метаболическая цитопротекция, sodium dichloroacetate, mitochondrial dysfunction, pyruvate dehydrogenase, metabolic cytoprotection

1. Agbenyega T., Planche T., Addo G. Bedo, Ansong D., Ofori A. Owusu, Bhattaram V. A., Nagaraja N. V., Shroads A. L., Henderson G. N., Hutson A. D., Derendorf H., Krishna S., Stacpoole P. W. Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children // The Journal of Clinical Pharmacology. - 2003. - Vol. 43. №4. - P. 386-396.

2. Ammini C. V., Canon J. Fernandez, Shroads A. L., Cornett R., Cheung J., James M. O., Henderson G. N., Grompe M., Stacpoole P. W Pharmacologic or genetic ablation of maleylacetoacetate isomerase increases levels of toxic tyrosine catabolites in rodents // Biochemical Pharmacology. - 2003. - Vol. 66. №10. - P. 2029-2038.

3. Ammini C. V., Stacpoole P. W. Biotransformation, Toxicology and Pharmacogenomics of Dichloroacetate // The Handbook of Environmental Chemistry. - 2003. - Vol. 3. - Part P. - P. 215-234.

4. Ayyanathan K., Kesaraju S., Dawson-Scully K., Weissbach H. Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage // PloS one. - 2012. - Vol. 7. №7. - e39949.

5. Babu E., Ramachandran S., CoothanKandaswamy V., Elangovan S., Prasad P.D., Ganapathy V., et al. Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate // Oncogene. - 2011. - Vol. 30. № 38. - P. 4026-4037.

6. Blackburn A. C., Coggan M., Tzeng H. F., Lantum H., Polekhina G., Parker M. W., Anders M. W., Board P. G. GSTZ1d: a new allele of glutathione transferase zeta and maleylacetoacetate isomerase // Pharmacogenetics. - 2001. - Vol. 11. №8. - P. 671-678.

7. Blackburn A. C., Tzeng H. F., Anders M. W., Board P. G. Discovery of a functional polymorphism in human glutathione transferase zeta by expressed sequence tag database analysis // Pharmacogenetics. - 2000. - Vol. 10. №1. - P. 49-57.

8. Bonnet S., Archer S. L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth // Cancer cell. - 2007. - Vol. 11. №1. - P. 37-51.

9. Cao W., Yacoub S., Shiverick K. T., Namiki K., Sakai Y., Porvasnik S., et al. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation // The Prostate. - 2008. - Vol. 68. №11. - P. 1223-1231.

10. Cornett R., James M. O., Henderson G. N., Cheung J., Shroads A. L., Stacpoole P. W. Inhibition of glutathione S-transferase zeta and tyrosine metabolism by dichloroaceate: a potential unifying mechanism for its altered biotransformation and toxicity // Biochem. Biophys. Res. Commun. - 1999. - Vol. 262. - P. 752-756.

11. Curry S. H., Lorenz A., Chu P. I., Limacher M., Stacpoole P. W. Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses // Biopharm. Drug Disp. -1991. - Vol. 12. - P. 375-390.

12. Curry S. H., Lorenz A., Henderson G. N., Mars D. R., Stacpoole P. W. Haemodialysis studies with dichloroacetate // European journal of clinical pharmacology. - 1991. - Vol. 40. №6. - P. 613-617.

13. Dhar S., Lippard S. J. Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate // Proceedings of the National Academy of Sciences of the United States of America. - 2009. -Vol. 106. №52. - P 22199-22204.

14. Duncan G. E., Perkins L. A., Theriaque D. W., Neiberger R. E., Stacpoole P. W. Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism // The Journal of Clinical Endocrinology & Metabolism. - 2004. - Vol. 89. №4. - P. 1733-1738.

15. Felitsyn N., Stacpoole P. W., Notterpek L. Dichloroacetate causes reversible demyelination in vitro: Potential mechanism for its neuropathic effect // Journal of Neurochemistry. - 2007. - Vol. 100. №2. - P. 429-436.

16. Flavin D. F. Non-Hodgkin's Lymphoma Reversal with Dichloroacetate // Journal of oncology. - 2010. - Vol. 2010. - Article ID 414726.

17. Gatenby R. A., Gillies R. J. Why do cancers have high aerobic glycolysis // Nature reviews Cancer. - 2004. - Vol. 4. №11 - P. 891-899.

18. Henderson G. N., Yan Z., James M. O., Davydova N, Stacpoole P. W. Kinetics and metabolism of chloral hydrate in children: identification of dichloroacetate as a metabolite // Biochem. Biophys. Res. Commun. - 1997. - №235. - P. 695-698.

19. Jackson V. N., Halestrap A. P. The kinetics, substrate, and inhibitor specificity of the monocarboxylate (lactate) transporter of rat liver cells determined using the fluorescent intracellular pH indicator, 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein // J. Biol. Chem. - 1996. - №271. - P. 861-868.

20. Jolley R. L. Basic issues in water chlorination: a chemical perspective // Water Chlorination: Chemistry, Environmental Impact and Health Effects. - 1985. - Vol. 5. - P 19-38.

21. Kaufmann P., Engelstad K., Wei Y., Jhung S., Sano M. C., Shungu D. C., Millar W. S., Hong X., Gooch C. L., Mao X., Pascual J. M., Hirano M., Stacpoole P. W., DiMauro S., DeVivo D. C. Dichloroacetate as a treatment for MELAS: A randomized, controlled clinical trial // Neurology. - 2006. - Vol. 66. №3. -P 324-330.

22. Kluza J., Corazao-Rozas P., Touil Y., Jendoubi M., Maire C., Guerreschi P., et al. Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants // Cancer research. - 2012. - Vol. 72. №19. - P 5035-5047.

23. Knoechel T. R., Tucker A. D., Robinson C. M., Phillips C., Taylor W., Bungay P. J., Kasten S. A., Roche T. E., Brown D. G. Regulatory roles of the N-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands // Biochemistry. - 2006. - Vol. 45. - P 402-415.

24. Landgraf R. R., Garrett T. J., Calcutt N. A., Stacpoole P. W., Yost R. A. MALDI-linear ion trap microprobe MS/MS studies of the effects of dichloroacetate on lipid content of nerve tissue // Analytical Chemistry. - 2007. - Vol. 79. №21. - P. 8170-8175.

25. Li T., Schultz I., Keys D. A., Campbell J. L., Fisher J. W. Quantitative evaluation of dichloroacetic acid kinetics in human -a physiologically based pharmacokinetic modeling investigation // Toxicology. - 2008. - Vol. 245. №1-2. - P 35-48.

26. Michelakis E. D., Webster L., Mackey J. R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer // British journal of cancer. 2008. - Vol. 99. №7. - P. 989-994.

27. Miller J. W., Uden P. C. Characterization of nonvolatile aqueous chlorination products of humic substances // Environ. Sci. Technol. - 1983. - №17. - P.150-157.

28. Roche T. E., Hiromasa Y. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer // Cell. Mol. Life Sci. - 2007. - Vol. 64. - P. 830-849.

29. Sasaki T., Gotow T., Shiozaki M., Sakaue F., Saito T., Julien J. P., Uchiyama Y., Hisanaga S. Aggregate formation and phosphorylation of neurofilament-L Pro22 Charcot-Marie-Tooth disease mutants // Human Molecular Genetics. - 2006. - Vol. 15. №6. - P 943-952.

30. Semenza G. L. HIF-1: upstream and downstream of cancer metabolism // Current opinion in genetics & development. - 2010. -Vol. 20. - №1. - P. 51-56.

31. Shroads A. L., Guo X., Dixit V., Liu H. P., James M. O., Stacpoole P. W. Age-Dependent Kinetics and Metabolism of Dichloroacetate: Possible Relevance to Toxicity // J. Pharmacol. Exp. Ther. - 2008. - Vol. 34. №3. - P. 1163-1171.

32. Stacpoole P. W. Review of the pharmacologic and therapeutic effects of diisopropylammonium dichloroacetate (DIPA) // J. Clin. Pharmacol. J. New Drugs. - 1969. - Vol. 9. - P. 282-291.

33. Stacpoole P. W. The pharmacology of dichloroacetate // Metabolism: clinical and experimental. - 1989. - Vol. 38. №11. - P. 1124-1144.

34. Stacpoole P. W., Barnes C. L., Hurbanis M. D., Cannon S. L., Kerr D. S. Treatment of congenital lactic acidosis with dichloroacetate // Archives of Disease in Childhood. - 1997. - Vol. 77. - P 535-541.

35. Stacpoole P. W., Gilbert L. R., Neiberger R. E., Carney P. R., Valenstein E., Theriaque D. W., Shuster J. J. Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate // Pediatrics. - 2008. - Vol. 121. №5. - P 1223-1228.

36. Stacpoole P. W., Henderson G. N., Yan Z., Cornett R., James M. O. Pharmacokinetics, metabolism and toxicology of dichloroacetate // Drug metabolism reviews. - 1998. - Vol. 30. №3. - P. 499-539.

37. Stacpoole P. W., Henderson G. N., Yan Z., James M. O. Clinical pharmacology and toxicology of dichloroacetate // Environmental health perspectives. - 1998. - Vol. 106. - Suppl. 4. - P 989-994.

38. Stacpoole P W,, KerrD. S., Barnes C., Bunch S. T., Carney P. R., Fennell E. M., Felitsyn N. M., Gilmore R. L., Greer M., Henderson G. N., Hutson A. D., Neiberger R. E., O’Brien R. G., Perkins L. E., Quisling R. G., Shroads A. L., Shuster J. J., Silverstein J. H., Theriaque D. W, Valenstein E. A controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children // Pediatrics. - 2006. - Vol. 117. - P. 1519-1531.

39. Stacpoole P. W., Kurtz T. L., Han Z., Langaee T. Role of Dichloroacetate in the Treatment of Genetic Mitochondrial Diseases // Advanced Drug Delivery Reviews. - 2008. - Vol. 60. №0. - P. 1478-1487.

40. Stacpoole P. W., Nagaraja N. V., Hutson A. D. Efficacy of dichloroacetate as a lactate-lowering drug // Journal of clinical pharmacology. - 2003. - Vol. 43. №7. - P. 683-691.

41. Stacpoole P. W, Shroads A. L., Felitsyn N. M., Notterpek L., Calcutt N. A. Mechanism of age dependence of dichloroacetate-induced peripheral neuropathy // Mitochondrion. - 2006. - Vol. 6. № 5. - P. 263-288.

42. Stacpoole P. W., Wright E. C., Baumgartner T. G., Bersin R. M., Buchalter S., Curry S. H., Duncan C. A., Harman E. M., Henderson G. N., Jenkinson S., Lachin J. M., Lorenz A,, Schneider S. H., Siegel J. H., Summer W. R., Thompson D., Wolfe C., Zorovich B. A controlled clinical trial of dichloroacetate treatment of lactic acidosis in adults // The New England Journal of Medicine. - 1992. - Vol. 327. №22. - P. 1564-1569.

43. Sutendra G., Michelakis E. D. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology // Frontiers in oncology. - 2013. - Vol. 3. - Article 38.

44. Tzeng H. F., Blackburn A. C., Board P. G., Anders M. W. Polymorphism- and species-dependent inactivation of glutathione transferase zeta by dichloroacetate // Chemical Research Toxicology. - 2000. - Vol. 139. №4. - P. 231-236.

45. Warburg O. On the origin of cancer cells // Science. -1956. - Vol. 123. - P 309-314.

46. Wong J. Y., Huggins G. S., Debidda M., Munshi N. C., De Vivo I. Dichloroacetate induces apoptosis in endometrial cancer cells // Gynecologic oncology. - 2008. - Vol. 109. №3. - P. 394-402.